Research Article

Evaluation of Serum MicroRNAs (miR-9-5p, miR-17-5p, and miR-148a-3p) as Potential Biomarkers of Breast Cancer

Xiaoqin Li,¹,² Xinyue Tang,¹ Kunsong Li,¹ and Ling Lu ³

¹Department of Oncology, Guangdong Second Provincial General Hospital, Guangzhou 510220, China
²Department of Pulmonary Medicine, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830011, China
³Department of Gynecology, First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China

Correspondence should be addressed to Ling Lu; 781554611@qq.com

Received 5 April 2021; Accepted 21 December 2021; Published 24 January 2022

Academic Editor: Luca Bertero

Copyright © 2022 Xiaoqin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. MicroRNAs (miRNAs) play important roles in the initiation and progression of cancers. The purpose of the present study was to evaluate the use of serum miRNA biomarkers in the early diagnosis of breast cancer. Methods. The expression levels of miR-9-5p, miR-17-5p, and miR-148a-3p were analyzed by quantitative reverse transcription-polymerase chain reaction in 49 patients with newly diagnosed breast cancer and 49 healthy controls. The associations between miR-9-5p, miR-17-5p, and miR-148a-3p levels and clinicopathological parameters were also analyzed. Regression analysis and sensitivity and specificity analyses were used to determine the diagnostic efficacy of the miRNAs. Results. Serum levels of miR-9-5p and miR-148a-3p were significantly higher in breast cancer patients than in healthy controls (both P < 0.05), but miR-17-5p levels were not different between the two groups (P = 0.996). Serum miR-9-5p levels were markedly higher in patients with human epidermal growth factor receptor 2- (HER2-) positive breast cancer than in those with HER2-negative breast cancer (P = 0.049). Serum levels of miR-9-5p and miR-148a-3p were positively correlated with the presence of breast cancer, and both miRNAs had high sensitivity and specificity for the diagnosis of breast cancer. Conclusions. These findings provide evidence that serum miR-9-5p and miR-148a-3p levels may be used as noninvasive biological markers for the clinical diagnosis of breast cancer.

1. Introduction

Breast cancer is one of the most common malignant cancers globally. It is the leading cause of cancer-specific deaths in women and the second leading cause of total deaths in women [1]. More than 270,000 new cases of breast cancer were confirmed in 2019 [2]. Although the prognosis of breast cancer patients has greatly improved, approximately 685,000 women died from this disease globally in 2020 [3]. Despite rapid developments in modern medical technology, the early diagnosis of breast cancer remains critical to improve the efficacy of treatments and the prognosis of this disease [4].

Sentinel lymph node biopsy, which has replaced axillary lymph node dissection, has been validated as the standard surgical procedure for the routine surgical management of breast cancer [5]. Similarly, molecular biomarkers, such as progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2), have been used to improve the prognostic stratification and predict the response to treatments [6]. However, given that blood collection has the advantages of simplicity, convenience, and noninvasiveness, liquid biopsy is becoming an increasingly relevant diagnostic method for oncological diseases. Thus, it is necessary to identify more accurate and reliable biomarkers that can be noninvasively, conveniently, and reliably used for the early diagnosis of breast cancer. Hence, noninvasive biomarkers, particularly blood microRNAs (miRNAs), have been extensively studied recently.

miRNAs are a diverse group of small noncoding RNA molecules with a length of 18 to 25 nucleotides [7]. They play important roles in various physiological and pathological processes related to cell proliferation, apoptosis, differentiation, and invasion [8]. Recent studies have demonstrated that the levels of some miRNAs correlated with clinical and biological features of cancers, and they were aberrantly
expressed in various types of cancers, such as lung cancer [9], certain myelomas [10], breast cancer [11], colorectal cancer [12], and hepatocellular carcinoma [13]. The evaluation of miRNA levels in blood, serum, or plasma may be helpful for tumor diagnosis [14].

miRNAs may participate in the development of breast cancer. miR-9-5p is highly expressed in breast cancer and is closely related to the biological behaviors of tumor cells, such as their promotion of angiogenesis, metastasis, and epithelial-mesenchymal transition [15, 16]. Studies have shown that miR-17-5p inhibited the proliferation and invasion of breast cancer cells. The low levels of miR-17-5p observed in the serum and cancer tissues of breast cancer patients are helpful for clinical diagnosis [17]. miR-148a-3p may be downregulated in the plasma of patients with breast cancer, and this is associated with lymph node metastasis [18].

The possibility of detecting cell-free miRNAs and the specific characteristics of miRNAs, such as tissue specificity and stability, indicates that miRNAs may be important biomarkers [19]. Although the serum level of miR-17-5p may be used as a marker for breast cancer recurrence [20], there are no previous studies showing the use of this biomarker in patients with newly diagnosed breast cancer. Some studies have found that miR-148a-3p was downregulated in breast cancer patients, but the authors of these studies did not further analyze the specificity or sensitivity of miR-148a-3p for the diagnosis of breast cancer [18].

In this study, we aimed to evaluate the levels of miR-9-5p, miR-17-5p, and miR-148a-3p in serum samples from breast cancer patients, to analyze their relationships with clinicopathological parameters, and to preliminarily explore their diagnostic value for breast cancer.

2. Materials

2.1. Patients. In this study, a total of 49 patients with a new (within 3 months) diagnosis of primary breast cancer and 49 age-matched healthy women, who were referred to the Guangdong Second Provincial General Hospital from January 12, 2019, to December 21, 2020, were recruited. Patients were included in the study if they (1) had not received radiotherapy, chemotherapy, or surgical resection before enrollment, (2) had no history of smoking or drinking, and (3) showed no evidence of organ metastasis. Patients were excluded if they (1) had severe liver or kidney damage, (2) had other malignant tumors, (3) had an autoimmune or other disease, or (4) had incomplete clinical data. The healthy controls were volunteers with normal mammography and ultrasonography results and without a history of malignant disease.

All of the subjects or their families provided written informed consent before participating in the study. This study was approved by the Ethics Committee of Guangdong Second Provincial General Hospital.

We collected the baseline characteristics of breast cancer patients and controls, including age, body mass index (BMI), age at first pregnancy, menopausal status, use of estrogen, and family history of breast cancer. Breast cancer was histologically confirmed for all patients. Clinical characteristics were collected through interviewer-administered questionnaires and/or from medical records. ER, PR, and HER2 status were determined by immunohistochemistry.

Peripheral blood was collected in BD vacutainer tubes (BD Biosciences, Franklin Lakes, NJ, U.S.A.) from each subject at the time of diagnosis and before commencing any therapy. Serum was separated within 2 hours of blood sample collection and then stored in aliquots in Eppendorf tubes at -80°C until analysis.

3. Methods

3.1. RNA Isolation and Reverse Transcription-Polymerase Chain Reaction Assay. Total RNA was extracted from serum samples using a miRNeasy extraction kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. The quality and quantity of the RNA samples were determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, U.S.A.). miRNA levels were determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). A microRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, U.S.A.) was used to reverse transcribe miRNA according to the manufacturer’s guidelines. Reactions were performed in an ABI 7500 Real-Time PCR System (Applied Biosystems). The levels of miR-9-5p, miR-17-3p, and miR-148a-3p were normalized to miR-16 levels using the Relative Expression Software Tool (REST version 2008).

3.2. Statistical Analysis. All analyses were performed using SPSS 22.0 software (SPSS Inc., Chicago, IL, U.S.A.). Normally distributed continuous variables were expressed as the mean values ± the standard errors, and Student’s t-test was used to compare parametric data between groups. Categorical variables were expressed as percentages, and a chi-square test was used to compare classified variables between groups. Pearson’s correlation was used to analyze the correlation between the level of miRNAs and the presence of breast cancer. Receiver operating characteristic curves were generated to evaluate the predictive values of the candidate miRNAs. A P value less than 0.05 was considered to be statistically significant.

4. Results

4.1. Baseline and Clinicopathological Characteristics of Breast Cancer Patients and Controls. The features of each group are summarized in Table 1. The mean ages of the patients with breast cancer and healthy control subjects were 55.6 ± 9.58 and 54.2 ± 8.77 years, respectively. No statistically significant differences were found in the baseline characteristics between the two groups for age, BMI, age at first pregnancy, menopausal status, use of estrogen, and family history of breast cancer (Table 1). The clinicopathological characteristics of the breast cancer patients are shown in Table 2.

4.2. Serum miRNA Levels in the Breast Cancer and Control Groups. We compared the serum levels of miR-9-5p, miR-17-5p, and miR-148a-3p in the case and control groups.
The serum levels of miRNA candidates were significantly higher in the postmenopause subgroup than those in the control group (miR-9-5p: 0.557 ± 0.326 vs. 0.356 ± 0.233, P = 0.001; miR-148a-3p: 2.609 ± 0.931 vs. 2.086 ± 0.552, P = 0.002). However, the levels of miR-9-5p and miR-148a-3p were not significantly different between the premenopause subgroup and the control group or between the pre- or postmenopause subgroups. Similarly, there was no significant difference in the levels of miR-17-5p between either the breast cancer subgroup and the control group or between the pre- or postmenopause breast cancer subgroups (Table 4).

To determine whether there were relationships between the serum levels of miR-9-5p, miR-17-5p, and miR-148a-3p and clinicopathological features, the breast cancer patients were stratified according to ER, PR, and HER2 status. There was no statistically significant difference in the serum levels of miR-17-5p between the different hormone status subgroups. The serum levels of miR-9-5p were significantly higher in the HR-positive patients than those in the HR-negative patients (0.577 ± 0.357 vs. 0.357 ± 0.25, P = 0.049). However, the levels of miR-9-5p and miR-148a-3p were not significantly different between the HER2-positive patients and the control subjects. Furthermore, the levels of miR-9-5p and miR-148a-3p were significantly higher in the ER-positive, ER-negative, PR-positive, and PR-negative breast cancer patient subgroups than those in the control group (Table 4).

### 4.4. Regression Analysis of miRNA Levels
Regression analysis was performed to analyze the relationships between miRNA levels (miR-9-5p, miR-17-5p, and miR-148a-3p) and breast cancer. The regression coefficient for miR-9-5p was 7.69 (95% confidence interval (CI): 5.88, 9.79), which indicated a significant positive correlation with the presence of breast cancer (P < 0.001). The miR-148a-3p levels were also significantly positively correlated with the presence of breast cancer (regression coefficient, 2.48; 95% CI: 0.77, 4.20; P < 0.001; Table 5).

### 4.5. Diagnostic Value of Serum miRNA Levels in Breast Cancer
We calculated sensitivity and specificity values for the use of miR-9-5p, miR-17-5p, and miR-148a-3p levels in breast cancer diagnosis. Higher sensitivity and specificity were observed for miR-9-5p (85.2%; 95% CI: 76.3, 99.1 and 93.7%; 95% CI: 72.5, 98.7, respectively) and miR-148a-3p (86.6%; 95% CI: 70.4, 92.8 and 87.5%; 95% CI: 73.8, 93.9, respectively) than for miR-17-5p (Table 6).

---

**Table 1: Baseline characteristics of breast cancer patients and controls.**

| Characteristics          | Cases (n = 49) | Controls (n = 49) | P      |
|--------------------------|----------------|------------------|--------|
| Age (years)              | 55.6 ± 9.58    | 54.2 ± 8.77      | 0.452  |
| BMI (kg/m²)              | 26.4 ± 5.47    | 27.3 ± 5.59      | 0.423  |
| Age of first pregnancy (years) | 20.5 ± 2.14    | 21.0 ± 2.11      | 0.247  |
| Menopause status         |                |                  | 0.655  |
| Premenopause             | 13 (26.5)      | 15 (30.6)        |        |
| Postmenopause            | 36 (73.5)      | 34 (69.4)        |        |
| Use of estrogens         |                |                  | 0.372  |
| Yes                      | 8 (16.3)       | 5 (10.2)         |        |
| No                       | 41 (83.7)      | 44 (89.8)        |        |
| Family history of breast cancer |            |                  | 0.092  |
| Yes                      | 5 (10.2)       | 1 (2.0)          |        |
| No                       | 44 (89.8)      | 48 (98.0)        |        |

Abbreviation: BMI: body mass index.

**Table 2: Clinicopathological characteristics of breast cancer patients.**

| Characteristics        | n (%)          |
|------------------------|----------------|
| Tumor size (mm)        | 8.2 ± 5.24     |
| Histology              |                |
| IDC                    | 40 (81.6)      |
| ILC                    | 2 (4.1)        |
| Others                 | 7 (14.3)       |
| ER status              |                |
| +                      | 30 (61.2)      |
| -                      | 19 (38.8)      |
| PR status              |                |
| +                      | 28 (57.1)      |
| -                      | 21 (42.9)      |
| HER2 status            |                |
| +                      | 35 (71.4)      |
| -                      | 14 (28.6)      |

Abbreviations: ER: estrogen receptor; IDC: invasive ductal carcinoma; HER2: human epidermal growth factor receptor 2; ILC: invasive lobular carcinoma; PR: progesterone receptor.

The levels of miR-9-5p and miR-148a-3p were significantly higher in the case group than those in the control group (miR-9-5p: 0.514 ± 0.327 vs. 0.356 ± 0.233, P = 0.002; miR-148a-3p: 2.557 ± 0.891 vs. 2.086 ± 0.552, P < 0.001), but no significant difference was found in the serum levels of miR-17-5p between the two groups (Table 3 and Figure 1).

### 4.3. Comparison of Serum miRNA Levels in Various Groups of Breast Cancer Patients
To examine the effect of menopausal status on the serum levels of miRNAs, we divided the case group into premenopause and postmenopause subgroups. The serum levels of miR-9-5p and miR-148a-3p were significantly higher in the postmenopause subgroup than those in the control group (miR-9-5p: 0.557 ± 0.326 vs. 0.356 ± 0.233, P = 0.001; miR-148a-3p: 2.609 ± 0.931 vs. 2.086 ± 0.552, P = 0.002). However, the levels of miR-9-5p and miR-148a-3p were not significantly different between the premenopause subgroup and the control group or between the pre- or postmenopause subgroups. Similarly, there was no significant difference in the levels of miR-17-5p between either the breast cancer subgroup and the control group or between the pre- or postmenopause breast cancer subgroups (Table 4).

**Table 3: Serum levels of the three microRNA candidates in the case and control groups.**

| miRNA          | Cases (n = 49) | Controls (n = 49) | P      |
|----------------|---------------|------------------|--------|
| miR-9-5p       | 0.514 ± 0.327 | 0.356 ± 0.233    | 0.002  |
| miR-17-5p      | 2.070 ± 0.593 | 2.177 ± 0.608    | 0.996  |
| miR-148a-3p    | 2.557 ± 0.891 | 2.086 ± 0.552    | <0.001 |

Data were expressed as the mean ± standard error.
Breast cancer is one of the most common malignant tumors and its incidence is increasing every year. Moreover, it shows a younger median age at diagnosis [2], which brings great challenges for its clinical prevention and treatment. Although surgery combined with concurrent radiotherapy and chemotherapy improves the clinical cure rate of early-stage breast cancer, there is a lack of effective treatment for advanced breast cancer [21]. Studies have shown that the benefits of breast cancer chemotherapy are rarely achieved in the subgroup of patients with "highly endocrine-sensitive" tumors, as defined by more than 50% of cells expressing both ER and PR, based on immunohistochemistry, and insufficient amplification of HER-2 [22]. Therefore, there is great interest in exploring the pathogenesis of breast cancer and identifying biological markers for early diagnosis. In recent years, miRNAs have attracted increasing research attention and they have become a new field of tumor biomarker research [18]. Studies have confirmed that miR-21 [23], miR-195 [24], and miR-140-3p [25] were related to the development of breast cancer.

In the present study, we analyzed the serum levels of three miRNAs, miR-9-5p, miR-17-5p, and miR-148a-3p, in breast cancer cases and healthy controls, and we found that the levels of miR-9-5p and miR-148a-3p were higher in the case group, whereas no significant difference in the serum levels of miR-17-5p was found between the two groups. Furthermore, we evaluated the levels of these three miRNAs according to clinicopathological features of breast cancer and found that the serum levels of miR-9-5p were significantly higher in the HER2-positive breast cancer patients compared to the HER2-negative patients. We then performed regression analysis and found that the levels of miR-9-5p and miR-148a-3p positively correlated with the presence of breast cancer. We further performed specificity and sensitivity analyses to determine their diagnostic value for breast cancer, and we found that the sensitivities of miR-9-5p and miR-148a-3p were 85.2 (95% CI: 76.3, 99.1) and 86.6 (95% CI: 70.4, 92.8), respectively, and the specificities of miR-9-5p and miR-148a-3p were 93.7 (95% CI: 72.5, 98.7) and 87.5 (95% CI: 73.8, 93.9), respectively.

In this study, miR-9-5p levels were found to be significantly upregulated in the breast cancer patients compared to the healthy controls. Consistent with our findings, Barbano et al. [14] also found elevated levels of miR-9-5p in tumor tissues compared to normal breast tissues. miR-9-5p, a member of the miR-9 family, is a highly conserved miRNA that is primarily expressed in the central nervous system [26]. The role of miR-9-5p in different tumors is inconsistent. It acts as a cancer-promoting miRNA in small cell lung cancer [27] and prostate cancer [28], but as a tumor suppressor in gastric cancer [29] and pancreatic cancer [30]. miR-9-5p participates in the proliferation, invasion, tumor metastasis, and angiogenesis of breast cancer through different target genes [31]. Studies have shown that miR-9-5p was an important factor affecting the prognosis of breast cancer, and its high expression levels suggest a poor prognosis for patients with breast cancer [32, 33]. Further analysis found that the serum miR-9-5p levels were significantly higher in the HER2-positive breast cancer patients compared to the HER2-negative patients, indicating that serum miR-9-5p levels may distinguish the HER2-positive subtype of breast cancer. Studies have also found that the expression levels of seven miRNAs (miR-183, miR-660, miR-29a, miR-93, miR-378, miR-4281, and miR-428) were significantly different in women with HER2-positive tumors compared to those with HER2-negative tumors [34].

The level of serum miR-148a-3p was significantly increased in the patients with breast cancer compared with the healthy controls. Studies have shown that miR-148a-3p may be closely related to the occurrence and development of tumors. The expression of miR-148a-3p was increased in prostate cancer patients [35], and the downregulation of miR-148a-3p in patients with gastric cancer may promote the occurrence of gastric cancer [36].

In thymic epithelial tumors, miR-148a-3p is used as a noninvasive marker of treatment efficacy and prognosis [37]. A previous study showed that, by inhibiting the expression of the ERα protein, miR-148a decreased the viability and migration of breast cancer cells induced by estrogen [38]. Contrary to our results, Li et al. [18] found that miR-148a-3p levels were downregulated in the plasma of patients with breast cancer, and they also found that miR-148a-3p was associated with lymph node metastasis. These conflicting results may be ascribed to differences in sample size, cancer subtypes, clinical characteristics and methodology, and the difficulties in transferring miRNA-based tests into routine diagnostic applications [39].

miR-17-5p, a member of the miR-17-19 family, is involved in a variety of tumorigenic mechanisms. It is related to the proliferation and apoptosis of tumor cells and has been the focus of much research in recent years [40]. Whereas miR-17-5p is particularly important in breast cancer, the miR-17-5p/miR-20a cluster acts as a tumor suppressor to directly inhibit the expression of amplified in breast cancer 1 and cyclin D1 in human breast cancer [41]. Yu et al. [42] found that miR-17-5p clusters mediated the migration and infiltration of breast cancer cells. In addition, miR-17-5p inhibited the migration and infiltration of MDA-MB-231 cells by inhibiting HBP1 [43]. Some studies have

![Figure 1: Serum levels of the three microRNA candidates in the case and control groups.](image-url)
| Menopause status | Cases | miR-9-5p | $P_1$ | $P_2$ | miR-17-5p | $P_1$ | $P_2$ | miR-148a-3p | $P_1$ | $P_2$ |
|------------------|-------|----------|-------|-------|-----------|-------|-------|-------------|-------|-------|
| Premenopause     | 0.395 ± 0.312 | 0.356 ± 0.233 | 0.587 | 0.502 | 2.138 ± 0.716 | 2.177 ± 0.608 | 0.844 | 0.110 | 2.410 ± 0.784 | 2.086 ± 0.552 | 0.092 | 0.149 |
| Postmenopause    | 0.557 ± 0.326 | 0.001 | 2.045 ± 0.551 | 0.307 | 2.609 ± 0.931 | 0.002 |
| ER status        |       |          |       |       |           |       |       |             |       |       |
| +                | 0.492 ± 0.329 | 0.035 | 0.895 | 2.156 ± 0.621 | 2.177 ± 0.608 | 0.883 | 0.282 | 2.645 ± 0.810 | 2.086 ± 0.552 | 0.001 | 0.121 |
| -                | 0.549 ± 0.330 | 0.008 | 1.933 ± 0.533 | 0.130 | 2.417 ± 1.014 | 0.089 |
| PR status        |       |          |       |       |           |       |       |             |       |       |
| +                | 0.484 ± 0.325 | 0.049 | 0.944 | 2.026 ± 0.605 | 2.177 ± 0.608 | 0.297 | 0.380 | 2.482 ± 0.955 | 2.086 ± 0.552 | 0.024 | 0.224 |
| -                | 0.563 ± 0.320 | 0.002 | 2.128 ± 0.587 | 0.756 | 2.656 ± 0.810 | 0.001 |
| HER2 status      |       |          |       |       |           |       |       |             |       |       |
| +                | 0.577 ± 0.357 | 0.001 | 0.049 | 2.118 ± 0.591 | 2.177 ± 0.608 | 0.659 | 0.797 | 2.570 ± 0.863 | 2.086 ± 0.552 | 0.002 | 0.481 |
| -                | 0.357 ± 0.251 | 0.985 | 1.949 ± 0.603 | 0.093 | 2.524 ± 0.992 | 0.035 |

Abbreviations: ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; $P_1$: $P$ value compared with controls; $P_2$: $P$ value compared among subgroups of cases.
found that the levels of miR-17-5p in the serum of breast cancer patients and in breast cancer tissues were lower than those in the serum and tissues of normal control subjects [20, 44]. On the contrary, we found no significant difference in the serum level of miR-17-5p in breast cancer patients compared to normal control subjects and miR-17-5p levels were poorly correlated with the presence of breast cancer. A possible reason for these contradictory results may be the different disease settings analyzed, as we focused on newly diagnosed breast cancer patients without any prior treatment. Conversely, the study by Wang et al. [20] was conducted among breast cancer patients who had cancer recurrence within 5 years after surgery, and Eichelser et al. [44] analyzed serum samples from 120 patients with primary breast cancer after surgery and before chemotherapy. Another reason for the inconsistent findings may be the small sample size of our study and consequently, the limited statistical power.

However, miR-9-5p and miR-148a-3p, which have higher sensitivity and specificity than miR-17-5p, may have a reasonable diagnostic accuracy for discriminating breast cancer patients from healthy subjects.

Some limitations of this study should be noted. First, sensitivity and specificity were not validated independently. Second, the sample size was relatively small, which limited the overall power of the study. Third, we did not collect follow-up data, such as disease recurrence and survival rates after treatment. Finally, we did not assess the diagnostic efficacy of combined miRNA-9-5p and miR-148a-3p levels.

6. Conclusions

The serum levels of miR-9-5p and miR-148a-3p were significantly upregulated in breast cancer patients compared with healthy subjects. Thus, miR-9-5p and miR-148a-3p may be regarded as biomarkers for the clinical diagnosis of breast cancer. However, these results should be confirmed in a larger validation study before these miRNAs can be used for the clinical diagnosis of breast cancer. Moreover, in the future, it will be necessary to evaluate the diagnostic efficacy of the serum levels of these miRNAs in larger, prospective studies that include multiple tumor types. Such data will be necessary to transfer these biomarkers into clinical practice.

**Abbreviations**

BC: Breast cancer
BMI: Body mass index
CI: Confidence interval
ER: Estrogen receptor
HER2: Human epidermal growth factor receptor 2
IDC: Invasive ductal carcinoma
IHC: Immunohistochemistry
ILC: Invasive lobular carcinoma
miRNAs: MicroRNAs
PR: Progesterone receptor
qRT-PCR: Quantitative reverse transcription-polymerase chain reaction
SE: Standard error.

**Data Availability**

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions.

**Conflicts of Interest**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Authors’ Contributions**

Ling Lu contributed to the conception and design of the work; Xiaojing Li and Xinyue Tang performed data collection. Xiaojing Li conducted the statistical analyses; Xinyue Tang wrote the draft of the manuscript. Kun Song Li made critical revisions to the manuscript. All authors read and approved the submitted version. Xiaojing Li and Xinyue Tang contributed equally to this work and should be considered as co-first authors.

**Acknowledgments**

The authors are grateful to all participants, laboratory staff, and professionals involved in the study for their valuable contributions. This study was supported by the General Project of Natural Science Foundation of Xinjiang Uygur Autonomous Region, grant number (2018D01C256), and Guangdong Second People’s Hospital Introduced Talent Research Startup Fund.
References

[1] L. A. Torre, R. L. Siegel, E. M. Ward, and A. Jemal, “Global cancer incidence and mortality rates and trends—an update,” Cancer Epidemiology, Biomarkers & Prevention, vol. 25, no. 1, pp. 16–27, 2016.

[2] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA: a Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.

[3] S. Lei, R. Zheng, S. Zhang et al., “Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020,” Cancer Communications, vol. 41, no. 11, pp. 1183–1194, 2021.

[4] T. A. Takahashi, C. I. Lee, and K. M. Johnson, “Breast cancer screening: does tomosynthesis augment mammography?,” Cleveland Clinic Journal of Medicine, vol. 84, no. 7, pp. 522–527, 2017.

[5] G. Manca, E. Tardelli, D. Rubello et al., “Sentinel lymph node biopsy in breast cancer,” Nuclear Medicine Communications, vol. 37, no. 6, pp. 570–576, 2016.

[6] J. Wesseling, C. Tinterri, A. Sapino et al., “An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer,” Virchows Archiv, vol. 469, no. 3, pp. 297–304, 2016.

[7] R. W. Carthew and E. J. Sontheimer, “Origins and mechanisms of miRNAs and siRNAs,” Cell, vol. 136, no. 4, pp. 642–655, 2009.

[8] H. Alder, C. Taccioli, H. Chen et al., “Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer,” Carcinogenesis, vol. 33, no. 9, pp. 1736–1744, 2012.

[9] H. Huang, Y. Jiang, Y. Wang et al., “miR-5100 promotes tumor growth in lung cancer by targeting Rab6,” Cancer Letters, vol. 362, no. 1, pp. 15–24, 2015.

[10] J. J. Zhao, J. Lin, D. Zhu et al., “miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-Catenin/BCL9 pathway,” Cancer Research, vol. 74, no. 6, pp. 1801–1813, 2014.

[11] Y. Patel, N. Shah, J. S. Lee et al., “A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth,” Oncotarget, vol. 7, no. 14, pp. 18295–18308, 2016.

[12] B. Li, Z. Xie, and B. Li, “miR-152 functions as a tumor suppressor in colorectal cancer by targeting PIK3R3,” Tumour Biology, vol. 37, no. 8, pp. 10075–10084, 2016.

[13] K. H. Jung, J. Zhang, C. Zhou et al., “Differentiation therapy for hepatocellular carcinoma: multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis,” Hepatology, vol. 63, no. 3, pp. 864–879, 2016.

[14] R. Barbano, B. Pasculli, M. Rendina et al., “Stepwise analysis of _MI9_ loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients,” Scientific Reports, vol. 7, no. 1, 2017.

[15] C. Backes, E. Meese, and A. Keller, “Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects,” Molecular Diagnosis & Therapy, vol. 20, no. 6, pp. 509–518, 2016.

[16] J. M. Gwak, H. J. Kim, E. J. Kim et al., “MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer,” Breast Cancer Research and Treatment, vol. 147, no. 1, pp. 39–49, 2014.

[17] F. Yang, Y. Li, L. Xu et al., “miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer,” Oncotargets and Therapy, vol. 10, pp. 543–550, 2017.

[18] X. Li, W. Zou, Y. Wang et al., “Plasma-based microRNA signatures in early diagnosis of breast cancer,” Molecular Genetics & Genomic Medicine, vol. 8, no. 5, article e1092, 2020.

[19] P. Kharaziha, S. Ceder, Q. Li, and T. Panaretakis, “Tumor cell-derived exosomes: a message in a bottle,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1826, no. 1, pp. 103–111, 2012.

[20] Y. Wang, J. Li, L. Dai, J. Zheng, Z. Yi, and L. Chen, “MiR-17-5p may serve as a novel predictor for breast cancer recurrence,” Cancer Biomarkers, vol. 22, no. 4, pp. 721–726, 2018.

[21] T. Shien and H. Iwata, “Adjuvant and neoadjuvant therapy for breast cancer,” Japanese Journal of Clinical Oncology, vol. 50, no. 3, pp. 225–229, 2020.

[22] E. H. Lips, L. Mulder, I. J. de Ronde et al., “Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics,” Breast Cancer Research and Treatment, vol. 131, no. 3, pp. 827–836, 2012.

[23] J. G. Han, Y. D. Jiang, C. H. Zhang et al., “A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer,” Annals of Surgical Treatment and Research, vol. 92, no. 2, pp. 55–66, 2017.

[24] M. M. Marques, A. F. Evangelista, T. Macedo et al., “Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer,” Clinics, vol. 73, article e184, 2018.

[25] N. Heydari, N. Nikbakhsh, F. Sadeghi et al., “Overexpression of serum MicroRNA-140-3p in premenopausal women with newly diagnosed breast cancer,” Gene, vol. 655, pp. 25–29, 2018.

[26] M. Kapsimali, W. P. Kloosterman, E. de Bruijn, F. Rosa, R. H. A. Plasterk, and S. W. Wilson, “MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system,” Genome Biology, vol. 8, no. 8, 2007.

[27] G. Li, F. Wu, H. Yang, X. Deng, and Y. Yuan, “miR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFBR2,” Biomedicine & Pharmacotherapy, vol. 96, pp. 1170–1176, 2017.

[28] L. Chen, W. Hu, G. Li, Y. Guo, Z. Wan, and J. Yu, “Inhibition of miR-9-5p suppresses prostate cancer progress by targeting Star1D3,” Cellular & Molecular Biology Letters, vol. 24, no. 1, 2019.

[29] C. Hang, H. S. Yen, C. Gong, H. Gao, Q.-., H. Mao, and J.-. X. Zhu, “MicroRNA-9 inhibits gastric cancer cell proliferation and migration by targeting neuropilin-1,” Experimental and Therapeutic Medicine, vol. 18, no. 4, pp. 2524–2530, 2019.

[30] J. Wang, B. Wang, H. Ren, and W. Chen, “miR-9-5p inhibits pancreatic cancer cell proliferation, invasion and glutamine metabolism by targeting G0T1,” Biochemical and Biophysical Research Communications, vol. 509, no. 1, pp. 241–248, 2019.

[31] S. Baroni, S. Romero-Cordoba, I. Plantamura et al., “Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts,” Cell Death & Disease, vol. 7, no. 7, 2016.

[32] M. H. Jang, H. J. Kim, J. M. Gwak, Y. R. Chung, and S. Y. Park, “Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer,” Human Pathology, vol. 68, pp. 69–78, 2017.
[33] C. W. Cheng, J. C. Yu, Y. H. Hsieh et al., “Increased cellular levels of microRNA-9 and microRNA-221 correlate with cancer stemness and predict poor outcome in human breast cancer,” *Cellular Physiology and Biochemistry*, vol. 48, no. 5, pp. 2205–2218, 2018.

[34] A. C. Godfrey, Z. Xu, C. R. Weinberg et al., “Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the sister study cohort,” *Breast Cancer Research*, vol. 15, no. 3, 2013.

[35] S. A. Dybos, A. Flatberg, J. Halgunset et al., “Increased levels of serum miR-148a-3p are associated with prostate cancer,” *APMIS*, vol. 126, no. 9, pp. 722–731, 2018.

[36] B. Song, J. du, D. F. Song, J. C. Ren, and Y. Feng, “Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer,” *Biological Research*, vol. 51, no. 1, 2018.

[37] T. Bellissimo, E. Russo, F. Ganci et al., “Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors,” *Cancer Biology & Therapy*, vol. 17, no. 1, pp. 79–82, 2016.

[38] F. Ma, Y. Feng, W. Li, Z. Li, T. Liu, and L. Li, “miR-148a suppresses estrogen-induced viability and migration of breast cancer cells via inhibition of estrogen receptor α expression,” *Experimental and Therapeutic Medicine*, vol. 13, no. 5, pp. 2515–2522, 2017.

[39] L. J. Guo and Q. Y. Zhang, “Decreased serum miR-181a is a potential new tool for breast cancer screening,” *International Journal of Molecular Medicine*, vol. 30, no. 3, pp. 680–686, 2012.

[40] S. W. Shan, D. Y. Lee, Z. Deng et al., “MicroRNA MiR-17 retards tissue growth and represses fibronectin expression,” *Nature Cell Biology*, vol. 11, no. 8, pp. 1031–1038, 2009.

[41] Z. Yu, C. Wang, M. Wang et al., “A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation,” *The Journal of Cell Biology*, vol. 182, no. 3, pp. 509–517, 2008.

[42] Z. Yu, N. E. Willmarth, J. Zhou et al., “MicroRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 18, pp. 8231–8236, 2010.

[43] C. M. C. Calvano Filho, D. C. Calvano-Mendes, K. C. Carvalho et al., “Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p,” *Tumour Biology*, vol. 35, no. 8, pp. 7733–7741, 2014.

[44] C. Eichelser, D. Flesch-Janys, J. Chang-Claude, K. Pantel, and H. Schwarzenbach, "Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression," *Clinical Chemistry*, vol. 59, no. 10, pp. 1489–1496, 2013.